Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

NCT00248560 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: docetaxel
DRUG: Gemcitabine

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]